AstraZeneca’s baxdrostat is approved by the FDA to treat blood pressure in patients with uncontrolled hypertension. The drug, to be known as Baxfendy, is the first of its kind to be used on this indication.
In particular, according to AstraZeneca’s news release on Monday, Baxfendy is the first aldosterone synthase inhibitor approved by the FDA for the treatment of hypertension. The medication is intended to be used along with other blood pressure medicines and can be used in people who have uncontrolled or treatment-resistant high blood pressure.
But with the approval, Baxfendy will go to the U.S. market of some 23 million treated patients, according to Ruud Dobber, executive vice president of AstraZeneca’s BioPharmaceuticals Business Unit, in a statement on Monday. The pharma estimates that some 1.4 billion people around the world suffer from hypertension.
AstraZeneca is also continuing to develop Baxfendy in other cardiovascular conditions, including primary aldosteronism, chronic kidney disease and the prevention of heart failure, all of which are in late-stage development.
The pharma has identified Baxfendy as one of the major products it plans to launch to achieve its revenue target of $80 billion by 2030, with a maximum expected sale of the product exceeding $5 billion. Leerink Partners had an even more optimistic outlook for the drug, setting a revenue “potential of up to $10bn if successful in additional indications.”
Data from the Phase 3 BaxHTN trial supported Monday’s approval, in which a 2-mg dose of Baxfendy reduced systolic blood pressure by 9.8 mmHg compared to placebo at 15 weeks, a statistically significant difference, according to an Aug. 2025 study published in The New England Journal of Medicine.
Even a lower 1-mg dose resulted in an 8.7-mmHg improvement over placebo, AstraZeneca said on Monday.
Oral Baxfendy works by inhibiting the aldosterone synthase enzyme, which can cause sodium to be retained in the body and, if unchecked, raise blood pressure. Baxfendy joined AstraZeneca in 2023, as the pharma acquired CinCor Pharma for $1.3 billion.
Mineralys Therapeutics is an active participant in the development of its own aldosterone synthase inhibitor lorundrostat, which is also being developed for hypertension, as well. In March, the FDA took lorundostat’s new drug application, and will decide in December.
AstraZeneca Expands Cardiovascular Treatment Portfolio
AstraZeneca has received regulatory approval for its new blood pressure medication, marking another important milestone in the company’s cardiovascular healthcare strategy. The approval allows AstraZeneca to expand treatment options for patients suffering from hypertension and related heart conditions.
High blood pressure remains one of the most common chronic health conditions worldwide, affecting millions of adults across different age groups. Medical experts continue to warn that uncontrolled hypertension increases the risk of heart disease, kidney failure, stroke, and other life-threatening complications. Because of this, pharmaceutical companies are investing heavily in next-generation therapies that offer improved effectiveness and better patient safety.
The newly approved medication is expected to provide physicians with another option for managing patients who struggle to maintain stable blood pressure levels with conventional treatments. Researchers involved in the development process focused on improving long-term cardiovascular outcomes while minimizing common side effects associated with older medications.
Importance of Regulatory Approval
Receiving regulatory approval is a major achievement for any pharmaceutical company because it confirms that the medication has passed strict evaluations related to safety, quality, and effectiveness. Before approval, the treatment underwent extensive clinical testing involving patients from multiple regions and healthcare settings.
The successful outcome demonstrates the growing importance of evidence-based medicine and advanced drug development technologies. It also reflects the increasing pressure on healthcare providers to deliver more personalized treatment solutions for chronic illnesses.
Market Impact and Industry Competition
The global market for hypertension medications continues to expand as healthcare systems prioritize preventive cardiovascular care. Pharmaceutical companies are competing to introduce therapies that can provide stronger blood pressure control while improving patient adherence to treatment plans.
Analysts believe the approval could intensify competition in the cardiovascular sector, particularly among companies developing combination therapies and precision medicine approaches. The demand for innovative treatments is expected to increase as aging populations and lifestyle-related health risks continue to rise worldwide.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
